A股異動丨國務院通過支持創新藥方案,提前炒作的創新藥股集體回調
國務院常務會議審議通過《全鏈條支持創新藥發展實施方案》,上週五消息公佈前提前獲炒作的創新藥概念股今早普遍回落。其中,凱因科技跌超8%,艾迪藥業跌超6%,榮昌生物、百奧泰、海欣股份、百利天恒、哈三聯跌超4%,賽隆藥業、百誠醫藥、仙琚製藥特寶生物和方盛製藥跌超3%。常務會議審議通過《全鏈條支持創新藥發展實施方案》,會議指出,發展創新藥關係醫藥產業發展,關係人民健康福祉。要全鏈條強化政策保障,統籌用好價格管理、醫保支付、商業保險、藥品配備使用、投融資等政策,優化審評審批和醫療機構考核機制,合力助推創新藥突破發展。同時要調動各方面科技創新資源,強化新藥創制基礎研究,夯實我國創新藥發展根基。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.